stockportfolio.pro
BMRN vs TECH: Which Stock Is the Better Buy?
BioMarin Pharmaceutical Inc. and Bio-Techne Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — BMRN vs TECH, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| BioMarin Pharmaceutical Inc. (BMRN) | Bio-Techne Corporation (TECH) | |
|---|---|---|
| Market cap | $10.9B | $11.0B |
| Revenue (latest FY) | $3.22B | $1.22B |
| Net income (latest FY) | $348.90M | $73.40M |
| Revenue growth (5y CAGR) | 11.6% | 10.5% |
| Net margin | 10.8% | 6.0% |
| Return on equity | 5.7% | 3.8% |
| P/E ratio | 40.4 | 101.2 |
| Dividend yield | — | 0.4% |
| Profitable years (of last 10) | 5 | 10 |
| Positive free cash flow | Yes | Yes |
See the full BMRN vs TECH breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open BMRN's full financials → Open TECH's full financials →More comparisons
Frequently asked questions
Which is bigger, BMRN or TECH?
Bio-Techne Corporation is larger by market capitalization — $11.0B versus $10.9B.
Which grows faster, BMRN or TECH?
Over the last five fiscal years, BioMarin Pharmaceutical Inc. grew revenue faster — 11.6%/yr versus 10.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.